With more than 50% of trials expected to be decentralized by 2024, many sponsors and CROs are learning that decentralizing clinical trials are not just for a pandemic. But despite adoption, there are still questions, myths and rumors about what it means to “decentralize a trial”.
Listen in as experts from Medable and Incyte compare traditional trials (design first, patient second) with patient-centered trials (patient first, design second) and discuss how adopting a decentralized approach can help any organization, regardless of size or therapeutic areas focus, reimagine their existing approach to choreograph a masterfully designed patient-centered trial.
Claire Marsden, Ph.D, VP, DCT Solutions at Medable and John Galvin, MD, MS, MPH, Senior medical Director, US Medical Affairs at Incyte discuss:
- The fundamentals of decentralized clinical trials
- Use cases for hybrid and fully decentralized approaches
- Benefits of designing patient-centered clinical trials